Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI

Gibbs, Peter; Liney, Gary; Lowry, Martin; Kneeshaw, Peter; Turnbull, Lindsay W.

doi:10.1016/j.breast.2003.10.002

Cited by 67 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the ability of WBI to sterilize unidentified disease elsewhere in the breast decreases as the incidental lesion size increases. Because MRI can detect tumors less than 1 cm with greater sensitivity than mammography or ultrasonography, 16 MRI could ensure PBI ipsilateral tumor control rates similar to those of patients receiving WBI. Our data suggest that MRI should be considered strongly for assessing PBI eligibility to minimize out-of-field failures.…”

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation

Al‐Hallaq

Mell

Bradley

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. In this retrospective study, the authors hypothesized that magnetic resonance imaging (MRI) would alter partial breast irradiation (PBI) eligibility by identifying cancers outside the PBI volume compared with mammography alone. METHODS. Since 2002, MRI was used nonselectively at the authors' institution for the staging of patients with nonmetastatic breast cancer. Of 450 consecutive patients with invasive breast cancer, 110 patients who were eligible for PBI were identified by using criteria outlined by National Surgical Adjuvant Breast and Bowel Project B‐39/Radiation Oncology Group trial 0413 based on mammography, ultrasonography, and initial pathology. In that trial, patients were randomized (stage I/II invasive cancers that measured ≤3 cm and ≤3 positive lymph nodes) to receive either whole‐breast radiotherapy or PBI. MRI reports were reviewed to determine whether MRI identified secondary lesions 1) within the same quadrant (multifocal), 2) in a different quadrant (multicentric), or 3) in the contralateral breast. These lesions were pathologically proven carcinoma and would have rendered the patient ineligible for PBI. RESULTS. MRI identified secondary lesions in 10% of patients (95% confidence interval [CI], 4.4%‐15.6%). Multifocal disease was identified in 3.6% (95% CI, 1.4%‐9%), multicentric disease was identified in 4.5% (95% CI, 2%‐10.2%), and contralateral disease was identified in 1.8% (95% CI, 0.5%‐6.4%). The proportion of patients with false‐positive MRI findings was 4.5% (95% CI, 2%‐10.2%). The positive predictive value of MRI was 72.2% (95% CI, 46.4%‐89.3%). CONCLUSIONS. MRI identified frequent secondary cancers that would not be removed routinely by surgery or targeted in the radiation field if treated with PBI. The current data suggest that MRI should be considered to assess PBI eligibility to minimize potential local failures. Cancer 2008. © 2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation

Al‐Hallaq

Mell

Bradley

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…The results presented in Figures 5,6,7,8,9, and 10 answer the five questions the study was set out to address. Figure 5 shows a plot of the average distance, in pixels, over all participants, between the location of the area of maximum metabolic activity selected on the MRI and the PET grayscale images when viewed side-by-side.…”

Section: Resultsmentioning

confidence: 99%

“…In this context, F-18-FDG PET [2][3][4][5] and highresolution and dynamic contrast-enhanced MRI [6][7][8][9][10][11] have steadily gained acceptance in addition to X-ray mammography and ultrasonography. Initial experience with combined PET (functional imaging) and MRI (anatomical localization) has yielded positive results, providing benefits compared to either modality alone [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Novel Genetic Algorithm Generated Schemes for Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) Image Fusion

Baum

Schmidt²,

Rafferty

et al. 2011

J Digit Imaging

View full text Add to dashboard Cite

The use and benefits of a multimodality approach in the context of breast cancer imaging are discussed. Fusion techniques that allow multiple images to be viewed simultaneously are discussed. Many of these fusion techniques rely on the use of color tables. A genetic algorithm that generates color tables that have desired properties such as satisfying the order principle, the rows, and columns principle, have perceivable uniformity and have maximum contrast is introduced. The generated 2D color tables can be used for displaying fused datasets. The advantage the proposed method has over other techniques is the ability to consider a much larger set of possible color tables, ensuring that the best one is found. We asked radiologists to perform a set of tasks reading fused PET/ MRI breast images obtained using eight different fusion techniques. This preliminary study clearly demonstrates the need and benefit of a joint display by estimating the inaccuracies incurred when using a side-by-side display. The study suggests that the color tables generated by the genetic algorithm are good choices for fusing MR and PET images. It is interesting to note that popular techniques such as the Fire/Gray and techniques based on the HSV color space, which are prevalent in the literature and clinical practice, appear to give poorer performance.

show abstract

“…The importance of morphological information was studied in a report from Gibbs et al, 26 who examined the role of MRI in differentiating less than 1 cm diameter benign from malignant lesions, using a high temporal resolution dynamic two-dimensional FSPGR technique (11 seconds) and high spatial resolution post-contrast T1-weighted imaging. Radiological assessment of the post-contrast data provided a diagnostic accuracy rate of 69%, compared with the exchange rate constant calculated from the DCE-MRI data, which revealed a diagnostic accuracy rate of 74%.…”

Section: Magnetic Resonance Imaging: Techniques and Protocolsmentioning

confidence: 99%

Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE)

Turnbull

Brown²,

Olivier³

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

on behalf of the COMICE Trial GroupHow to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are ...

show abstract

Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI

Cited by 67 publications

References 20 publications

Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation

Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation

Evaluation of Novel Genetic Algorithm Generated Schemes for Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) Image Fusion

Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE)

Contact Info

Product

Resources

About